NCT01497821View on ClinicalTrials.gov

AMG 172 First in Human Study in Patients With Kidney Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

January 31, 2015

Conditions
Renal Cell AdenocarcinomaClear Cell Renal CarcinomaClear Cell Renal Cell CarcinomaRenal Cell Carcinoma
Interventions
DRUG

AMG 172

AMG 172 is an antibody drug conjugate

Trial Locations (4)

63110

Research Site, St Louis

69120

Research Site, Heidelberg

85258

Research Site, Scottsdale

94805

Research Site, Villejuif

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY